Table 2. Interactions between presence of CC and other risk factors in predicting cardiac event (event n = 483/1608).
| Subgroup | HR (95% CI) | P value | Interaction P value | |
| Age | Non-CC | 1.030 (1.021–1.038) | < 0.001 | 0.250 |
| CC | 1.017 (1.002–1.033) | 0.030 | ||
| Male Sex | Non-CC | 0.962 (0.785–1.179) | 0.709 | 0.020 |
| CC | 1.588 (1.051–2.400) | 0.028 | ||
| Body mass index | Non-CC | 0.981 (0.956–1.007) | 0.142 | 0.547 |
| CC | 1.023 (0.873–1.199) | 0.776 | ||
| Systolic blood pressure | Non-CC | 0.995 (0.992–0.999) | 0.020 | 0.202 |
| CC | 1.000 (0.994–1.007) | 0.948 | ||
| Hypertension | Non-CC | 1.417 (1.117–1.798) | 0.004 | 0.194 |
| CC | 1.050 (0.686–1.607) | 0.822 | ||
| Diabetes mellitus | Non-CC | 1.717 (1.408–2.094) | < 0.001 | 0.592 |
| CC | 1.472 (0.976–2.220) | 0.065 | ||
| Atrial fibrillation | Non-CC | 1.614 (1.323–1.968) | < 0.001 | 0.452 |
| CC | 1.351 (0.895–2.040) | 0.152 | ||
| Coronary artery disease | Non-CC | 1.116 (0.904–1.379) | 0.306 | 0.107 |
| CC | 1.618 (1.034–2.533) | 0.035 | ||
| Peripheral artery disease | Non-CC | 1.593 (1.187–2.137) | 0.002 | 0.256 |
| CC | 1.046 (0.525–2.085) | 0.898 | ||
| Cerebrovascular disease | Non-CC | 1.223 (0.955–1.565) | 0.111 | 0.321 |
| CC | 0.922 (0.561–1.514) | 0.749 | ||
| Cancer | Non-CC | 1.375 (1.074–1.761) | 0.011 | 0.016 |
| CC | 0.649 (0.376–1.119) | 0.120 | ||
| COPD | Non-CC | 1.514 (1.207–1.900) | < 0.001 | 0.795 |
| CC | 1.434 (0.888–2.317) | 0.141 | ||
| β-blockers | Non-CC | 1.642 (1.258–2.144) | < 0.001 | 0.888 |
| CC | 1.731 (1.043–2.875) | 0.034 | ||
| ACEIs/ARBs | Non-CC | 1.314 (1.030–1.677) | 0.028 | 0.606 |
| CC | 1.163 (0.745–1.816) | 0.507 | ||
| Loop diuretics | Non-CC | 4.148 (3.066–5.610) | < 0.001 | 0.035 |
| CC | 2.047 (1.137–3.685) | 0.017 | ||
| C-reactive protein | Non-CC | 0.999 (0.996–1.003) | 0.694 | 0.590 |
| CC | 0.997 (0.991–1.003) | 0.386 | ||
| Hemoglobin | Non-CC | 0.854 (0.817–0.893) | < 0.001 | 0.846 |
| CC | 0.870 (0.772–0.981) | 0.023 | ||
| Albumin | Non-CC | 0.612 (0.525–0.713) | < 0.001 | 0.114 |
| CC | 0.834 (0.598–1.164) | 0.286 | ||
| Log-BNP | Non-CC | 2.725 (2.249–3.302) | < 0.001 | 0.282 |
| CC | 1.891 (1.139–3.138) | 0.014 | ||
| eGFR | Non-CC | 0.974 (0.970–0.979) | < 0.001 | 0.028 |
| CC | 0.986 (0.978–0.994) | 0.001 | ||
| Sodium | Non-CC | 0.925 (0.901–0.949) | < 0.001 | <0.001 |
| CC | 1.017 (0.973–1.064) | 0.454 | ||
| LVEF | Non-CC | 0.985 (0.978–0.991) | < 0.001 | 0.939 |
| CC | 0.985 (0.970–1.000) | 0.050 | ||
| TR-PG | Non-CC | 1.001 (1.000–1.002) | 0.006 | 0.474 |
| CC | 0.996 (0.983–1.010) | 0.584 | ||
| RV-FAC | Non-CC | 0.992 (0.981–1.003) | 0.134 | 0.314 |
| CC | 1.004 (0.980–1.028) | 0.761 |
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CC: cardiac cachexia; COPD: chronic obstructive pulmonary disease; CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; Log-BNP: log-transformed B-type natriuretic peptide; LVEF: left ventricular ejection fraction; TR-PG: tricuspid regurgitation pressure gradient; RV-FAC: right ventricular fractional area change.